Director, Bioconjugation

Position Summary

Director of Bioconjugation to shape bioconjugation strategy across ADC and antibody–RNA conjugate (ARC/AOC) portfolios (antibody-based conjugates). Lead a team of bioconjugation scientists; set conjugation strategy and partner with Chemistry on linker–payload design across small molecule cytotoxic payloads, oligonucleotide payloads, targeted protein degrader payloads, and dual-payload formats. Build platform capabilities and drive conjugate strategy from target selection through candidate nomination and transition to development.

• - Lead bioconjugation team; set scientific direction and deploy resources to portfolio priorities.
• - Co-develop enterprise bioconjugation strategy with Global Chemistry (chemistry selection, site‑specificity, DAR distribution, address oligonucleotide vs small‑molecule chemistry challenges).
• - Lead/co‑lead discovery program teams; own conjugate design and delivery strategy from concept to candidate selection/transition.
• - Partner across functions (Discovery Chemistry, Biologics/Protein Engineering, Discovery Biology/Translational Sciences, DMPK, Toxicology, Development); manage external relationships (academia, technology partners, CROs).
• - Represent bioconjugation in governance/portfolio reviews; ensure discovery choices are manufacturable and analytically tractable.
• - Champion data capture/standardization and computational/ML‑enabled design.

• - Bachelor’s 15+ yrs OR Master’s 12+ yrs OR PhD 8+ yrs; 6+ yrs leadership.
• - Degree in relevant scientific discipline.
• - Deep hands‑on bioconjugation expertise (cysteine/lysine conjugation; site‑specific/enzymatic; click/bioorthogonal; cleavable/non‑cleavable linker design).
• - Experience with cytotoxic small‑molecule ADCs; antibody–RNA/oligonucleotide conjugates; degrader‑antibody/dual‑payload architectures.
• - Experience with highly potent small‑molecule payloads (safe handling/containment).
• - Program leadership (advance candidates to nomination/clinical development).
• - Ability to interpret analytical data (RP‑HPLC, SEC, HIC, IEX, LC‑MS/HRMS, CE‑SDS).
• - Excellent communication; influence senior stakeholders.

• - Progressive leadership (8+ yrs) as bioconjugation lead on discovery teams.
• - Oligonucleotide therapeutics depth (siRNA/ASO) for conjugates; glycan‑mediated bioconjugation; targeted protein degradation; dual/multi‑payload orthogonal strategies.
• - CMC/tech‑transfer exposure; IND‑enabling package support; high‑throughput/automated conjugation and computational/ML‑guided design; business development/due diligence; strong scientific reputation.

• - Comprehensive benefits including medical, dental, vision, life, disability; wellbeing and retirement/financial protection.
• - Flexible Time Off (U.S. exempt) plus 11 paid holidays; other vacation/holiday details for non‑exempt/Rayze Bio/PR.